GEMS Construct Modular Gene Editing for Scalable Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapies face scalability and commercialization challenges in translating proof-of-concept studies into widely available treatments for a broader spectrum of patients and conditions, despite promising results from gene modification techniques.
Innovation Solution
A gene editing multi-site (GEMS) construct is introduced into a genome, comprising flanking insertion sequences and a GEMS sequence with multiple nuclease recognition sequences, allowing for precise insertion and editing of genes, such as those encoding chimeric antigen receptors, into safe harbor sites within cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene modification techniques are used to create personalized cell therapies, then therapeutic efficacy is improved, but scalability and commercial viability deteriorate
Solution Approach 1:
The patent divides the gene editing process into modular components: a standardized GEMS construct backbone containing multiple nuclease recognition sequences, flanking homology arms for targeted integration, and interchangeable guide RNA sequences. This segmentation allows the core editing machinery to be reused across different therapies while only the guide sequences need customization, thereby improving scalability without compromising therapeutic efficacy.
Solution Approach 2:
The GEMS construct is designed as a universal platform that can target multiple genomic sites simultaneously through its plurality of nuclease recognition sequences. This multi-functional design enables a single construct to perform various gene editing operations (insertion, deletion, correction) at different locations in the genome, reducing the need for multiple separate editing operations and enhancing both productivity and versatility.
2Manufacturing precision
If multiple gene editing operations are performed separately, then precision is improved, but process complexity and time increase
Solution Approach 1:
The patent merges multiple nuclease recognition sequences within a single GEMS construct, allowing simultaneous or sequential targeting of multiple genomic sites in one integrated platform. This consolidation reduces the number of separate editing operations required, simplifying the overall process while maintaining the precision of individual editing events through controlled nuclease activation at each target site.
Solution Approach 2:
The GEMS construct is pre-designed with multiple nuclease recognition sequences and flanking homology arms in a ready-to-use configuration. This preliminary preparation of the editing platform allows for rapid deployment across different therapeutic applications without requiring complex reconfiguration, thereby reducing process complexity while preserving editing precision through predetermined target site optimization.
3Reliability
If personalized cell therapies are developed for each patient, then treatment effectiveness is improved, but manufacturing cost and time increase
Solution Approach 1:
The patent segments the therapy development process into a reusable standardized GEMS construct platform and patient-specific guide RNA sequences. This segmentation allows the majority of the manufacturing process to be standardized and scaled, while only the minimal customization of guide sequences is required for each patient, thereby significantly reducing manufacturing time while maintaining personalized treatment effectiveness.
Solution Approach 2:
The standardized GEMS construct serves as a master template that can be rapidly copied and adapted for different therapeutic applications. This copying approach allows simultaneous production of multiple therapy variants from a single validated platform, reducing manufacturing time and costs while maintaining the personalized efficacy needed for different patients through simple guide sequence modifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables stable integration and expression of therapeutic proteins in cells, enhancing the scalability and commercial viability of cell therapies by facilitating precise genetic modifications across a range of conditions.
Implementation Method 1
said guide target sequence binds a guide polynucleotide following insertion of said GEMS construct at said insertion site
Data Source
AI summary
Disclosed herein is a polynucleotide construct comprising one or more nuclease recognition sequences upstream and downstream of a Gene editing multi-site that comprises a plurality of nuclease recognition sequences. The plurality of nuclease recognition sequences facilitate insertion of one or more exogenous donor genes into the host cell.